Logo image of RYTM

RHYTHM PHARMACEUTICALS INC (RYTM) Stock Fundamental Analysis

NASDAQ:RYTM - Nasdaq - US76243J1051 - Common Stock - Currency: USD

56.07  -1.67 (-2.89%)

After market: 56.07 0 (0%)

Fundamental Rating

2

Overall RYTM gets a fundamental rating of 2 out of 10. We evaluated RYTM against 572 industry peers in the Biotechnology industry. The financial health of RYTM is average, but there are quite some concerns on its profitability. RYTM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RYTM had negative earnings in the past year.
In the past year RYTM has reported a negative cash flow from operations.
In the past 5 years RYTM always reported negative net income.
In the past 5 years RYTM always reported negative operating cash flow.
RYTM Yearly Net Income VS EBIT VS OCF VS FCFRYTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

RYTM has a Return On Assets of -110.83%. This is in the lower half of the industry: RYTM underperforms 78.69% of its industry peers.
RYTM has a Return On Equity of -263.89%. This is in the lower half of the industry: RYTM underperforms 72.65% of its industry peers.
Industry RankSector Rank
ROA -110.83%
ROE -263.89%
ROIC N/A
ROA(3y)-41.33%
ROA(5y)-48.24%
ROE(3y)-67.27%
ROE(5y)-66.47%
ROIC(3y)N/A
ROIC(5y)N/A
RYTM Yearly ROA, ROE, ROICRYTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

With an excellent Gross Margin value of 88.72%, RYTM belongs to the best of the industry, outperforming 91.83% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RYTM Yearly Profit, Operating, Gross MarginsRYTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
RYTM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RYTM has more shares outstanding
The debt/assets ratio for RYTM is higher compared to a year ago.
RYTM Yearly Shares OutstandingRYTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
RYTM Yearly Total Debt VS Total AssetsRYTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 3.03 indicates that RYTM is not in any danger for bankruptcy at the moment.
RYTM has a better Altman-Z score (3.03) than 74.78% of its industry peers.
A Debt/Equity ratio of 0.72 indicates that RYTM is somewhat dependend on debt financing.
RYTM has a worse Debt to Equity ratio (0.72) than 78.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Altman-Z 3.03
ROIC/WACCN/A
WACC9.4%
RYTM Yearly LT Debt VS Equity VS FCFRYTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

RYTM has a Current Ratio of 3.49. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
RYTM has a Current ratio of 3.49. This is comparable to the rest of the industry: RYTM outperforms 41.56% of its industry peers.
RYTM has a Quick Ratio of 3.34. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.34, RYTM is in line with its industry, outperforming 41.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.49
Quick Ratio 3.34
RYTM Yearly Current Assets VS Current LiabilitesRYTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

RYTM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.54%.
The Revenue has grown by 123.45% in the past year. This is a very strong growth!
EPS 1Y (TTM)-37.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.95%
Revenue 1Y (TTM)123.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.76%

3.2 Future

The Earnings Per Share is expected to grow by 31.57% on average over the next years. This is a very strong growth
Based on estimates for the next years, RYTM will show a very strong growth in Revenue. The Revenue will grow by 65.55% on average per year.
EPS Next Y-37.76%
EPS Next 2Y8.56%
EPS Next 3Y18.67%
EPS Next 5Y31.57%
Revenue Next Year60.21%
Revenue Next 2Y52.62%
Revenue Next 3Y59.78%
Revenue Next 5Y65.55%

3.3 Evolution

RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RYTM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYTM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYTM Price Earnings VS Forward Price EarningsRYTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYTM Per share dataRYTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as RYTM's earnings are expected to grow with 18.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.56%
EPS Next 3Y18.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RYTM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (2/21/2025, 8:00:01 PM)

After market: 56.07 0 (0%)

56.07

-1.67 (-2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)02-26 2025-02-26/bmo
Inst Owners97.18%
Inst Owner Change-2.51%
Ins Owners0.61%
Ins Owner Change0.27%
Market Cap3.45B
Analysts83.53
Price Target74.65 (33.14%)
Short Float %9.38%
Short Ratio10.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.12%
Min EPS beat(2)5.17%
Max EPS beat(2)11.07%
EPS beat(4)3
Avg EPS beat(4)2.84%
Min EPS beat(4)-6.55%
Max EPS beat(4)11.07%
EPS beat(8)5
Avg EPS beat(8)2.36%
EPS beat(12)8
Avg EPS beat(12)4.72%
EPS beat(16)10
Avg EPS beat(16)-25.64%
Revenue beat(2)1
Avg Revenue beat(2)-0.36%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)0.25%
Revenue beat(4)1
Avg Revenue beat(4)-3.12%
Min Revenue beat(4)-6.39%
Max Revenue beat(4)0.25%
Revenue beat(8)3
Avg Revenue beat(8)3.48%
Revenue beat(12)5
Avg Revenue beat(12)19.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.5%
PT rev (3m)4.14%
EPS NQ rev (1m)4.91%
EPS NQ rev (3m)4.91%
EPS NY rev (1m)0.62%
EPS NY rev (3m)2%
Revenue NQ rev (1m)7.12%
Revenue NQ rev (3m)7.12%
Revenue NY rev (1m)0.75%
Revenue NY rev (3m)2.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.88
P/FCF N/A
P/OCF N/A
P/B 22.57
P/tB 23.55
EV/EBITDA N/A
EPS(TTM)-4.47
EYN/A
EPS(NY)-2.63
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS2.25
BVpS2.48
TBVpS2.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.83%
ROE -263.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.72%
FCFM N/A
ROA(3y)-41.33%
ROA(5y)-48.24%
ROE(3y)-67.27%
ROE(5y)-66.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.49
Quick Ratio 3.34
Altman-Z 3.03
F-Score3
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)18.84%
Cap/Depr(5y)99.08%
Cap/Sales(3y)4.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.95%
EPS Next Y-37.76%
EPS Next 2Y8.56%
EPS Next 3Y18.67%
EPS Next 5Y31.57%
Revenue 1Y (TTM)123.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.76%
Revenue Next Year60.21%
Revenue Next 2Y52.62%
Revenue Next 3Y59.78%
Revenue Next 5Y65.55%
EBIT growth 1Y-118.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.2%
EBIT Next 3Y16.24%
EBIT Next 5YN/A
FCF growth 1Y30.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.84%
OCF growth 3YN/A
OCF growth 5YN/A